Pathogen Blood Testing

Direct detection, conventional fungal markers, and how blood testing can support the protocol

Blood testing can add another layer when deeper or systemic fungal involvement is being explored.

What this page is for

This page helps separate:

direct detection of fungal material in blood
immune-response testing
conventional high-risk fungal testing
research-oriented or integrative approaches

NIIM's pathogen blood test approach

The NIIM assay uses a two-part process.

Part 1: Direct visualisation

Fresh and processed blood are examined under the microscope for:

normal white blood cells
atypical human cells
non-human cells, including bacteria, fungi, moulds, protozoa, and parasites

Part 2: Genetic identification

If non-human forms are seen, the lab can proceed to DNA-based identification.

That may include:

PCR for bacterial pathogens
fungal or mould DNA sequencing for species identification

Group member experience with NIIM test:

I did the NIIM CTC and got a clean Step 1 result, which means: no high-burden visible infection on that day's blood draw. It does not mean all is clear for Bartonella, chronic Borrelia, low-level Babesia, or even Aspergillus unless Step 2 was actually triggered. And it was not triggered. It's worth noting that with the Step 1 tools Aspergillus detection figures of approx 50% apply to people with active, invasive, symptomatic infection — for someone carrying a low-level, non-invasive, asymptomatic Aspergillus burden (which is far more common in people with compromised immunity), the likelihood of Step 1 microscopy catching it drops close to zero, meaning the NIIM testing process would return a clean result while a low-level but still immune suppressing fungal load quietly continues

Why is this different?

This is not antibody testing.

It aims to detect the pathogen itself using pretty basic microscopy, and if it finds it, it looks for its DNA rather than your immune response to it.

NOTE: Bartonella isn't even included in NIIM's Step 2 PCR panel at all — not because it's rare, but because standard Bartonella PCR performs so poorly on whole blood that it would give false reassurance anyway. Detecting chronic Bartonella requires a specialised enrichment process that only a handful of labs worldwide do well.

Important distinction

Mainstream medicine treats frank fungemia as a marker of severe invasive disease.

Research assays like NIIM sit in a greyer zone:

microscopic fungal elements
circulating fungal DNA
low-level or subclinical presence under investigation.

Conventional fungal blood-testing options

Blood culture for fungi

Best for: confirmed bloodstream infection.

Limit: low sensitivity, especially for Aspergillus.

β-D-glucan

Detects: a pan-fungal cell-wall component in serum.

Useful for: serial monitoring in higher-risk settings.

Limit: not species-specific, with possible false positives.

Galactomannan

Detects: an Aspergillus cell-wall antigen.

Useful for: invasive aspergillosis workups, especially in high-risk patients.

Aspergillus PCR

Detects: circulating Aspergillus DNA.

Useful for: faster detection than culture in specialist settings.

Aspergillus PCR in whole blood achieves a sensitivity of 71–86%.

Candida PCR or T2Candida

Detects: circulating Candida DNA.

Useful for: earlier detection than standard culture in some high-risk settings.

Antibody tests are different

Fungal antibody testing looks at the host's immune response.

That can be relevant in some contexts, but it does not prove active invasive infection.

When blood testing is most relevant

Blood testing becomes more relevant when there is concern for:

deep or systemic burden
high-risk immunosuppression
persistent fever despite antibiotics
lung infiltrates or sino-orbital symptoms
severe oncology or transplant risk settings

How blood testing can support the protocol

Baseline

Consider fungal testing if clinically indicated, plus:

ALT and AST
CBC
kidney function

During protocol

Day 10: liver enzymes
Week 4: CMP and CBC
Repeat fungal markers if they were abnormal at baseline and your practitioner thinks they are useful for response tracking

Key takeaways

Direct detection looks for pathogen or DNA, not antibodies.
Circulating fungal DNA is real and measurable.
Standard tests still matter in high-risk settings.
Species identification can help tailor therapy.
Negative testing does not always rule out meaningful fungal involvement.

Selected references

Interpret blood-testing results in clinical context. A positive PCR or DNA signal does not automatically prove viable invasive infection.

Explore the anti-fungal guide

Choose any section below.